Immetas and GC Biopharma Collaborate on mRNA Therapeutics for Autoimmune Diseases
Thursday, October 12, 2023
Immetas Therapeutics and GC Biopharma have entered into a research collaboration to develop novel mRNA therapeutics for the treatment of autoimmune diseases.
Under the terms of the collaboration agreement, Immetas will be responsible for identification of therapeutic targets within innate immune pathways, the development and characterisation of payload molecules, the determination of specific disease indications, and the formulation of strategic plans for translational and clinical development.
This collaboration unites Immetas' unique platform for controlling innate immune pathways with GC Biopharma's specialised messenger RNA (mRNA) therapeutic and lipid nanoparticle (LNP) delivery technologies. Both companies will collaborate on subsequent development activities, which may include preclinical studies, clinical trials, and regulatory submissions.
With their combined expertise in mRNA and nanoparticle delivery, this partnership provides the opportunity to jointly pursue numerous projects aimed at significantly enhancing the treatment options available to individuals suffering from autoimmune disorders.
